Evelo Biosciences Inc
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis . The company is also developing EDP1867, a non-live pharmaceutical preparation fo… Read more
Market Cap & Net Worth: Evelo Biosciences Inc (EVLO)
Evelo Biosciences Inc (PINK:EVLO) has a market capitalization of $4.76 ($4.76) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #45390 globally and #14282 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Evelo Biosciences Inc's stock price $0.00 by its total outstanding shares 9521 (9.52K).
Evelo Biosciences Inc Market Cap History: 2018 to 2025
Evelo Biosciences Inc's market capitalization history from 2018 to 2025. Data shows change from $2.48 Million to $4.76 (-85.59% CAGR).
Evelo Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Evelo Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of EVLO by Market Capitalization
Companies near Evelo Biosciences Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Evelo Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Evelo Biosciences Inc Historical Marketcap From 2018 to 2025
Between 2018 and today, Evelo Biosciences Inc's market cap moved from $2.48 Million to $ 4.76, with a yearly change of -85.59%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $4.76 | 0.00% |
| 2024 | $4.76 | -99.19% |
| 2023 | $585.54 | -99.81% |
| 2022 | $306.58K | -73.48% |
| 2021 | $1.16 Million | -49.79% |
| 2020 | $2.30 Million | +197.78% |
| 2019 | $773.11K | -68.79% |
| 2018 | $2.48 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Evelo Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.76 USD |
| MoneyControl | $4.76 USD |
| MarketWatch | $4.76 USD |
| marketcap.company | $4.76 USD |
| Reuters | $4.76 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.